Daewoong Pharma Cash Flow Conversion Efficiency

Latest as of September 2025: 0.057x

Daewoong Pharma cash flow conversion efficiency. Based on the latest financial reports, Daewoong Pharma (069620) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩57.53 Billion ≈ $38.99 Million USD) by net assets (₩1.00 Trillion ≈ $680.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Daewoong Pharma (2007–2024)

Cash flow conversion efficiency of Daewoong Pharma from 2007 to 2024. This chart illustrates how Daewoong Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 069620 stock price for real-time trading data and today's change.

Daewoong Pharma Cash Flow Conversion Ratio Explained

Daewoong Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Daewoong Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Daewoong Pharma ranked by their cash flow conversion efficiency. Also see Daewoong Pharma market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Thai Vegetable Oil Public Company Limited BK:TVO	-0.048x
Limin Chemical Co Ltd SHE:002734	0.028x
Fujian Yuanli Active Carbon Co Ltd SHE:300174	0.018x
Shanghai Anoky Group SHE:300067	-0.006x
Qiming Information Technology Co Ltd SHE:002232	-0.005x
Shanghai Huitong Energy Co Ltd SHG:600605	-0.034x
Ardmore Shpng NYSE:ASC	0.041x
Qt Group Oyj HE:QTCOM	0.064x

Annual Cash Flow Conversion Efficiency for Daewoong Pharma (2007–2024)

The table below shows the annual cash flow conversion efficiency of Daewoong Pharma from 2007 to 2024. Review Daewoong Pharma free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩926.98 Billion ≈ $628.20 Million	₩51.49 Billion ≈ $34.90 Million	0.056x	-66.35%
2023-12-31	₩802.97 Billion ≈ $544.16 Million	₩132.57 Billion ≈ $89.84 Million	0.165x	+3.52%
2022-12-31	₩741.22 Billion ≈ $502.32 Million	₩118.21 Billion ≈ $80.11 Million	0.159x	+180.10%
2021-12-31	₩702.41 Billion ≈ $476.01 Million	₩39.99 Billion ≈ $27.10 Million	0.057x	-60.80%
2020-12-31	₩695.25 Billion ≈ $471.16 Million	₩100.98 Billion ≈ $68.43 Million	0.145x	+60.35%
2019-12-31	₩635.92 Billion ≈ $430.95 Million	₩57.60 Billion ≈ $39.03 Million	0.091x	+15.90%
2018-12-31	₩607.81 Billion ≈ $411.90 Million	₩47.50 Billion ≈ $32.19 Million	0.078x	-52.52%
2017-12-31	₩631.54 Billion ≈ $427.98 Million	₩103.94 Billion ≈ $70.44 Million	0.165x	+547.03%
2016-12-31	₩604.55 Billion ≈ $409.70 Million	₩15.38 Billion ≈ $10.42 Million	0.025x	-58.87%
2015-12-31	₩580.24 Billion ≈ $393.22 Million	₩35.89 Billion ≈ $24.32 Million	0.062x	+8.59%
2014-12-31	₩455.51 Billion ≈ $308.69 Million	₩25.95 Billion ≈ $17.58 Million	0.057x	-53.94%
2013-12-31	₩437.96 Billion ≈ $296.80 Million	₩54.16 Billion ≈ $36.70 Million	0.124x	+6.17%
2012-12-31	₩386.59 Billion ≈ $261.98 Million	₩45.02 Billion ≈ $30.51 Million	0.116x	-46.45%
2011-12-31	₩362.42 Billion ≈ $245.60 Million	₩78.82 Billion ≈ $53.42 Million	0.217x	+93.60%
2008-12-31	₩278.85 Billion ≈ $188.97 Million	₩31.33 Billion ≈ $21.23 Million	0.112x	+17.33%
2007-12-31	₩269.57 Billion ≈ $182.68 Million	₩25.81 Billion ≈ $17.49 Million	0.096x	--

About Daewoong Pharma

KO:069620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$796.92 Million

₩1.18 Trillion KRW

Market Cap Rank

#9593 Global

#247 in Korea

Share Price

₩102200.00

Change (1 day)

+1.09%

52-Week Range

₩99100.00 - ₩194000.00

All Time High

₩272265.92